Showing 1431-1440 of 1716 results for "".
- Consensus Paper Addresses S. aureus Exacerbated ADhttps://practicaldermatology.com/news/consensus-paper-addresses-s-aureus-exacerbated-ad/2468445/A significant unmet need exists for a single topical atopic dermatitis (AD) therapy effective against all symptoms—including pruritis, S. aureus-driven AD exacerbation, infection, and inflammation—across AD severity levels, according to a panel of six pediatric dermatologists who participated in
- Tralokinumab-ldrm 300 mg/2 mL Single-Dose Autoinjector Available in UShttps://practicaldermatology.com/news/tralokinumab-ldrm-300-mg2-ml-single-dose-autoinjector-available-us/2468195/The Adbry® (tralokinumab-ldrm) 300 mg/2 mL single-dose autoinjector is now available in the United States for patients 12 and older with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisab
- Alopecia Areata Linked to Increased Psychiatric, Autoimmune Conditionshttps://practicaldermatology.com/news/alopecia-areata-linked-increased-psychiatric-autoimmune-conditions/2467632/A new retrospective analysis indicated that patients with newly diagnosed alopecia areata (AA) tended to have higher prevalence of psychiatric and autoimmune comorbidities. Researchers for the study focused on adolescents and adults aged 12-64 years diagnosed with AA (compared to a control
- FDA Approves New Tralokinumab-ldrm Autoinjectorhttps://practicaldermatology.com/news/fda-approves-new-tralokinumab-ldrm-autoinjector/2467047/The US Food and Drug Administration (FDA) announced the approval of a new tralokinumab-ldrm 300-mg single-dose autoinjector for adult patients. Adbry® (LEO Pharma Inc.), a high-affinity fully human monoclonal antibody, is currently indicated in the US for the treatment of moderate-to-sever
- FDA Approves Adbry Autoinjector for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis (AD)https://practicaldermatology.com/news/fda-approves-adbry-autoinjector-treatment-adults-moderate-severe-atopic-dermatitis-ad/2467043/The FDA has approved LEO Pharma's Adbry (tralokinumab-ldrm) 300 mg single-dose autoinjector for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older.1 The new autoinjector (300 mg/2 mL) will provide another option for adult patients in addit
- Co-occurring Autistic Spectrum Disorder Mediates ADHD on Atopic Dermatitis, Acnehttps://practicaldermatology.com/news/co-occurring-asd-mediates-impact-of-adhd-on-atopic-dermatitis-and-acne-a-retrospective-cohort-study/2462200/Both male and females who were diagnosed with attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) showed different risks for acne and eczema, according to a study. "Our study is the first to examine the association between ASD, ADHD, and two of the most commo
- Demystifying Itch: Does S. aureus Kickstart a Molecular Chain Reaction That Culminates in the Urge to Scratch?https://practicaldermatology.com/news/demystifying-itch-does-s-aureus-kickstart-a-molecular-chain-reaction-that-culminates-in-the-urge-to-scratch/2462148/Staphylococcus aureus may cause itch by acting directly on nerve cells. The findings, based on research in mice and in human cells, are reported Nov. 22 in Cell. In eczema and atopic dermatitis, the equilibrium of microorganisms that keep skin he
- ‘Bliss’ Compound May Hold Out Hope for Autoimmune Skin Diseasehttps://practicaldermatology.com/news/bliss-compound-may-hold-out-hope-for-autoimmune-skin-disease/2462112/A marijuana-like compound holds out promise as a new treatment for a severe autoimmune skin disease called skin lupus, suggests a recent study out of George Washington University. If the results of the mouse study can be replicated in human trials, the compound, known as anandamide
- Does Vitiligo-associated Autoimmunity Reduce Morbidity and Mortality?https://practicaldermatology.com/news/does-vitiligo-associated-autoimmunity-reduced-morbidity-and-mortality/2462014/Vitiligo-associated autoimmunity may play a role in reducing morbidity and mortality, according to a study in the Journal of Investigative Dermatology. When researchers investigated the mortality of patients with vitiligo in a population-base
- Regenerative Medicine in Action: Scarless Wound Recovery May Be Possible with New Autologous Blood Techniquehttps://practicaldermatology.com/news/regenerative-medicine-in-action-scarless-wound-recovery-may-be-possible-with-new-autologous-blood-technique/2461982/A new technology that utilizes autologous blood to produce three-dimensional microvascular implants may help make scarless wound recovery a reality. Led by Professor Joo H. Kang from the Department of Biomedical Engineering at UNIST, the team developed a microfluidic system capable